Skip to main content
NASDAQ:CYTH

Cyclo Therapeutics Competitors

$7.00
+0.25 (+3.70 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.85
$7.25
50-Day Range
$6.58
$9.27
52-Week Range
$3.55
$17.75
Volume46,102 shs
Average Volume826,338 shs
Market Capitalization$44.51 million
P/E RatioN/A
Dividend YieldN/A
Beta-1

Competitors

Cyclo Therapeutics (NASDAQ:CYTH) Vs. LYB, IFF, WLK, BAK, NEU, and SXT

Should you be buying CYTH stock or one of its competitors? Companies in the industry of "industrial organic chemicals" are considered alternatives and competitors to Cyclo Therapeutics, including LyondellBasell Industries (LYB), International Flavors & Fragrances (IFF), Westlake Chemical (WLK), Braskem (BAK), NewMarket (NEU), and Sensient Technologies (SXT).

LyondellBasell Industries (NYSE:LYB) and Cyclo Therapeutics (NASDAQ:CYTH) are both basic materials companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

67.6% of LyondellBasell Industries shares are owned by institutional investors. Comparatively, 2.4% of Cyclo Therapeutics shares are owned by institutional investors. 0.2% of LyondellBasell Industries shares are owned by insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares LyondellBasell Industries and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LyondellBasell Industries4.23%24.09%5.80%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Analyst Recommendations

This is a summary of current ratings and target prices for LyondellBasell Industries and Cyclo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LyondellBasell Industries291002.38
Cyclo Therapeutics00103.00

LyondellBasell Industries currently has a consensus price target of $92.1579, suggesting a potential downside of 19.21%. Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than LyondellBasell Industries.

Risk & Volatility

LyondellBasell Industries has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.

Valuation & Earnings

This table compares LyondellBasell Industries and Cyclo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LyondellBasell Industries$34.73 billion1.10$3.40 billion$9.6211.86
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A

LyondellBasell Industries has higher revenue and earnings than Cyclo Therapeutics.

Summary

LyondellBasell Industries beats Cyclo Therapeutics on 8 of the 12 factors compared between the two stocks.

International Flavors & Fragrances (NYSE:IFF) and Cyclo Therapeutics (NASDAQ:CYTH) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

94.4% of International Flavors & Fragrances shares are owned by institutional investors. Comparatively, 2.4% of Cyclo Therapeutics shares are owned by institutional investors. 0.4% of International Flavors & Fragrances shares are owned by insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares International Flavors & Fragrances and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Flavors & Fragrances7.44%11.00%5.10%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Analyst Recommendations

This is a summary of current ratings and target prices for International Flavors & Fragrances and Cyclo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Flavors & Fragrances031002.77
Cyclo Therapeutics00103.00

International Flavors & Fragrances currently has a consensus price target of $147.5385, suggesting a potential upside of 4.48%. Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than International Flavors & Fragrances.

Risk & Volatility

International Flavors & Fragrances has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.

Valuation & Earnings

This table compares International Flavors & Fragrances and Cyclo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Flavors & Fragrances$5.14 billion6.84$455.87 million$6.1722.89
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A

International Flavors & Fragrances has higher revenue and earnings than Cyclo Therapeutics.

Summary

International Flavors & Fragrances beats Cyclo Therapeutics on 8 of the 12 factors compared between the two stocks.

Westlake Chemical (NYSE:WLK) and Cyclo Therapeutics (NASDAQ:CYTH) are both basic materials companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

28.2% of Westlake Chemical shares are owned by institutional investors. Comparatively, 2.4% of Cyclo Therapeutics shares are owned by institutional investors. 73.1% of Westlake Chemical shares are owned by insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Westlake Chemical and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Westlake Chemical5.14%4.74%2.25%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Risk & Volatility

Westlake Chemical has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Westlake Chemical and Cyclo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Westlake Chemical37502.13
Cyclo Therapeutics00103.00

Westlake Chemical currently has a consensus price target of $86.1429, suggesting a potential downside of 17.25%. Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than Westlake Chemical.

Valuation & Earnings

This table compares Westlake Chemical and Cyclo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Westlake Chemical$8.12 billion1.64$421 million$3.2631.93
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A

Westlake Chemical has higher revenue and earnings than Cyclo Therapeutics.

Summary

Westlake Chemical beats Cyclo Therapeutics on 9 of the 12 factors compared between the two stocks.

Braskem (NYSE:BAK) and Cyclo Therapeutics (NASDAQ:CYTH) are both oils/energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

0.5% of Braskem shares are owned by institutional investors. Comparatively, 2.4% of Cyclo Therapeutics shares are owned by institutional investors. 0.0% of Braskem shares are owned by insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Braskem and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Braskem-20.56%-962.43%-13.59%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Risk & Volatility

Braskem has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Braskem and Cyclo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Braskem03202.40
Cyclo Therapeutics00103.00

Braskem currently has a consensus price target of $17.00, suggesting a potential downside of 14.23%. Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than Braskem.

Earnings and Valuation

This table compares Braskem and Cyclo Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Braskem$12.72 billion0.62$-643,890,000.00($1.71)-11.59
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A

Cyclo Therapeutics has lower revenue, but higher earnings than Braskem.

NewMarket (NYSE:NEU) and Cyclo Therapeutics (NASDAQ:CYTH) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares NewMarket and Cyclo Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewMarket$2.19 billion1.76$254.29 millionN/AN/A
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A

NewMarket has higher revenue and earnings than Cyclo Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for NewMarket and Cyclo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewMarket0000N/A
Cyclo Therapeutics00103.00

Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Given Cyclo Therapeutics' higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than NewMarket.

Risk & Volatility

NewMarket has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500.

Profitability

This table compares NewMarket and Cyclo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewMarket12.58%37.86%13.54%
Cyclo Therapeutics-903.35%-4,537.83%-278.21%

Insider and Institutional Ownership

55.7% of NewMarket shares are owned by institutional investors. Comparatively, 2.4% of Cyclo Therapeutics shares are owned by institutional investors. 16.9% of NewMarket shares are owned by insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

NewMarket beats Cyclo Therapeutics on 7 of the 11 factors compared between the two stocks.

Cyclo Therapeutics (NASDAQ:CYTH) and Sensient Technologies (NYSE:SXT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Earnings & Valuation

This table compares Cyclo Therapeutics and Sensient Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclo Therapeutics$1.01 million44.07$-7,530,000.00N/AN/A
Sensient Technologies$1.32 billion2.74$82.05 million$2.9628.94

Sensient Technologies has higher revenue and earnings than Cyclo Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cyclo Therapeutics and Sensient Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cyclo Therapeutics00103.00
Sensient Technologies00103.00

Cyclo Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 257.14%. Sensient Technologies has a consensus price target of $70.00, suggesting a potential downside of 18.28%. Given Cyclo Therapeutics' higher possible upside, analysts clearly believe Cyclo Therapeutics is more favorable than Sensient Technologies.

Volatility & Risk

Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500. Comparatively, Sensient Technologies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.

Profitability

This table compares Cyclo Therapeutics and Sensient Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cyclo Therapeutics-903.35%-4,537.83%-278.21%
Sensient Technologies5.12%13.65%6.97%

Insider & Institutional Ownership

2.4% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Sensient Technologies shares are held by institutional investors. 31.9% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 0.8% of Sensient Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sensient Technologies beats Cyclo Therapeutics on 7 of the 10 factors compared between the two stocks.


Cyclo Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LyondellBasell Industries logo
LYB
LyondellBasell Industries
2.2$114.07+3.1%$38.14 billion$34.73 billion32.41Analyst Downgrade
Gap Down
International Flavors & Fragrances logo
IFF
International Flavors & Fragrances
2.5$141.21+1.8%$35.15 billion$5.14 billion42.28Earnings Announcement
Analyst Report
News Coverage
Westlake Chemical logo
WLK
Westlake Chemical
2.3$104.10+2.0%$13.34 billion$8.12 billion34.47Analyst Report
Insider Selling
Braskem logo
BAK
Braskem
0.8$19.82+2.6%$7.90 billion$12.72 billion-3.50Analyst Upgrade
NewMarket logo
NEU
NewMarket
1.0$352.77+1.3%$3.86 billion$2.19 billion15.36
Sensient Technologies logo
SXT
Sensient Technologies
1.8$85.66+0.9%$3.62 billion$1.32 billion53.87
Amyris logo
AMRS
Amyris
1.5$11.67+5.8%$3.40 billion$152.56 million-5.23Gap Down
Methanex logo
MEOH
Methanex
1.6$37.98+1.3%$2.89 billion$2.78 billion-22.74Analyst Report
Renewable Energy Group logo
REGI
Renewable Energy Group
2.4$63.17+8.3%$2.80 billion$2.64 billion4.56Analyst Report
Analyst Revision
Gap Down
Green Plains logo
GPRE
Green Plains
1.6$26.75+4.1%$1.19 billion$2.42 billion-9.42
Codexis logo
CDXS
Codexis
1.5$18.29+3.8%$1.18 billion$68.46 million-52.26Gap Down
Gevo logo
GEVO
Gevo
1.3$5.90+19.3%$1.17 billion$24.49 million-3.62Earnings Announcement
News Coverage
Gap Down
Westlake Chemical Partners logo
WLKP
Westlake Chemical Partners
2.1$26.40+0.8%$929.25 million$1.09 billion14.35
FutureFuel logo
FF
FutureFuel
1.3$14.91+1.1%$652.21 million$205.23 million5.73Dividend Announcement
Unusual Options Activity
REX American Resources logo
REX
REX American Resources
0.9$80.40+4.6%$481.76 million$418.03 million123.69Gap Down
Green Plains Partners logo
GPP
Green Plains Partners
1.8$11.94+3.1%$277.10 million$82.39 million6.82Gap Down
Aemetis logo
AMTX
Aemetis
1.5$9.39+4.0%$254.46 million$202 million-6.71Earnings Announcement
Analyst Revision
TOMI Environmental Solutions logo
TOMZ
TOMI Environmental Solutions
0.0$2.82+1.8%$47.41 million$6.35 million0.00Upcoming Earnings
News Coverage
TANH
Tantech
0.6$1.07+0.9%$38.41 million$49.23 million0.00
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.